Online inquiry

IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13158MR)

This product GTTS-WQ13158MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13158MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15903MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ14336MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ13074MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ15430MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ11488MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ4814MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ3092MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ751MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW